Evoked Compound Action Potentials for Parkinson's Disease (eCAP-PD) Study
The purpose of this research is to see whether the study device, the Evoke® SCS System, is safe and works to treat Parkinson’s disease symptoms. The Evoke Spinal Cord Stimulator is FDA approved for and routinely used to treat chronic pain, but it has not been tested to know whether it helps treat Parkinson’s Disease symptoms.
Executive Administration & Musculoskeletal Advisory Board at NYU Langone Orthopedic Hospital | NYU Langone Health
NYU Langone Orthopedic Hospital is led by an executive administration and musculoskeletal advisory board.
Executive Administration at NYU Langone Hospital—Long Island | NYU Langone Health
NYU Winthrop Hospital achieves excellence through the leadership of its senior executives and medical experts.
Executive Administration at NYU Langone Hospital—Suffolk | NYU Langone Health
We use cookies and similar tools to give you the best website experience. By using our site, you accept ...
Executive Physicals | NYU Langone Health
NYU Langone offers executive physicals, providing diagnostic testing and medical referrals.
Exercise & Cardiovascular Wellness Programs | NYU Langone Health
The team at NYU Langone’s Center for the Prevention of Cardiovascular Disease helps people start and maintain a heart-healthy exercise routine.
Exhaled and nasal nitric oxide in children and adults with chronic wet cough
Patients with chronic wet cough will undergo diagnostic evaluation to determine if there is diagnostic utility and an association between their levels of forced exhaled nitric oxide and nasal nitric oxide and ultimate diagnosis of either protracted bacterial bronchitis, cough variant asthma, primary ciliary dyskinesia or cystic fibrosis. The evaluation will be made through the combined use of nasal nitric oxide testing using a non-invasive research device (non FDA approved), forced exhaled nitric oxide testing and further standard of care diagnostic tests and procedures as clinically indicated which may include : blood test, bronchoscopy with bronchoalveolar lavage and endobronchial biopsy, sweat test, CT scans, etc.
EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE
This study is an expanded access protocol (EAP), meaning it is testing how effective and safe it would be to use medicine called nonconforming Idecabtagene Vicleucel (a batch of CAR-T-cell therapy or treatment that is suitable for EAP’s clinical use but not suitable for commercial release) in blood cancer patients who have been prescribed it as part of their routine care. The patients will first receive a medicine called lymphodepleting chemotherapy and then will be treated with the study medicine. The study team will check how the patients are doing and monitor all the patients for side effects and discomforts throughout the study. All patients will have their blood samples taken during the study to see if their blood counts are within acceptable ranges. Doctors will follow up with all patients for up to 3 months after they receive the study medicine to check for safety and to see how the study medicine is changing their cancer.
Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas
This is an intermediate-size expanded access protocol to provide ONC201 to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 through clinical trials.
EXpanding Prenatal cell free DNA screening Across moNogenic Disorders (EXPAND)
The purpose of this research is to develop and validate a single gene Non-Invasive Prenatal Test. The development of this investigational single-gene noninvasive prenatal testing (sgNIPT) for conditions such as cystic fibrosis (CF), spinal muscular atrophy (SMA), Sickle cell disease, alpha thalassemia (a-thalassemia) and beta thalassemia (ß-thalassemia) could provide information about the possibility that a child will be born with a serious health condition, in some cases in the absence of paternal screening.